Project Grant R21DA061167

Award Date 7/15/24
Completion Date 6/30/26
Dollars Obligated $790K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Durham, NC 27713, USA
Similar Awards
This Project Grant award of $147,486 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund two multi-method studies to characterize the impact of the veterinary tranquilizer xylazine on people who use drugs (PWUD) in North Carolina and Maine. The first study in North Carolina aims to describe PWUD's perceptions, experiences, and the impacts of xylazine, including related complications like wounds and overdoses, through surveys...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $212,200 to the Research Triangle Institute (RTI International) to conduct a 24-month mixed-methods study examining the feasibility and acceptability of a community-based drug checking (CBDC) program operating through a syringe service program (SSP) in rural and tribal communities in Minnesota. The goal is to use the CBDC program to collect...
The National Institute on Drug Abuse (NIDA) awarded a $907,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Tufts University School of Medicine. The grant, titled "Examination of Xylazine Exposure and the Risk of Skin and Soft Tissue Infections in People Who Inject Drugs," will fund a 3-year study to prospectively recruit 200 people who inject drugs (PWID) in Lowell, Massachusetts and examine the association between xylazine exposure and the...
This Project Grant award of $1,322,026.00, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a community-based, longitudinal study to investigate the growing crisis of injection-related wounds and skin and soft tissue infections (IWSTIs) among people who inject drugs (PWID) in North Carolina. The key products and services to be delivered under this grant include: 1) Observing, examining, and categorizing IWSTIs...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $233,250 to The Washington University in St. Louis to conduct research on the prevalence of the drug xylazine in the illicit drug supply and the etiology of xylazine-related invasive infections. The research aims to: 1) conduct active surveillance of the local illicit drug supply in St. Louis, Missouri using mass spectrometry and microbiologic...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $238,500 to the University of Pittsburgh to conduct research on the effects of xylazine and opioids on prefrontal cortex inhibitory transmission. The research aims to understand xylazine's cell signaling profiles and interactions with opioids at the circuit level, as xylazine is becoming highly prevalent in illicit opioid supplies and poses an...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support a mixed methods study to develop a natural language processing (NLP) algorithm to identify patients exposed to the veterinary sedative xylazine, which has become an emerging threat during the U.S. opioid crisis. The total award of $146,922 will fund in-depth interviews with people who use drugs and medical providers in Rhode Island to...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $506,000.00 to the Scripps Research Institute to prepare and investigate monoclonal antibodies that can block the mechanism of action and adverse effects of the drug xylazine. Xylazine has been increasingly detected as an adulterant in illicit drug mixtures and is linked to a growing number of overdose deaths. The research aims to generate a...
This $387,750 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research by Mercer University to investigate the molecular pharmacology of the drug xylazine and its effects on adrenoceptors. The research aims to assess xylazine's binding affinity and functional profiles at different adrenoceptor subtypes expressed in vascular smooth muscle cells, as well as directly test the hypothesis that...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $231,000 to the University of Rochester to conduct research on the pharmacological properties of the drug xylazine and its metabolites. The key objectives are to determine if xylazine and its metabolites act as agonists, antagonists, or positive allosteric modulators at the mu and kappa opioid receptors, as well as the sigma 1 and sigma...

GROWING XYLAZINE SUPPLY IN NC: A COMMUNITY-BASED INVESTIGATION OF EXPOSURE AND HEALTH CONSEQUENCES - PROJECT SUMMARY/ABSTRACT WE PROPOSE A COMMUNITY-BASED, LONGITUDINAL, MIXED-METHODS STUDY TO INVESTIGATE THE GROWING CRISIS OF XYLAZINE EXPOSURE AMONG PEOPLE WHO USE DRUGS (PWUD) IN THE SOUTHEASTERN US. THE OFFICE OF NATIONAL DRUG CONTROL POLICY RECENTLY LISTED XYLAZINE AS AN EMERGING THREAT AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) WARNED OF XYLAZINE'S GROWING INVOLVEMENT IN FENTANYL OVERDOSE DEATHS. AMONG ALL US REGIONS IN 2020-2021, THE SOUTH EXPERIENCED THE LARGEST INCREASE IN XYLAZINE-INVOLVED OVERDOSE (OD) DEATHS AND THE LARGEST RISE IN XYLAZINE-POSITIVE DRUG SEIZURES. YET, THERE REMAINS A PAUCITY OF INFORMATION ON ADULTERATION PATTERNS IN LOCAL MARKETS, THE IMPACT OF (UN)WITTING EXPOSURE AMONG CONSUMERS, HOW CONSUMERS ARE RESPONDING TO XYLAZINE, AND DRUG USE BEHAVIORS PLACING PEOPLE AT INCREASED RISK FOR ATYPICAL ODS AND NOVEL WOUNDS. CDC RECOMMENDS TESTING ILLICIT DRUGS FOR XYLAZINE TO CLARIFY PREVALENCE IN DRUG SUPPLIES AND PROVIDE ACTIONABLE INTELLIGENCE TO INFORM RESPONSE. COMMUNITY-BASED DRUG CHECKING (CBDC) WILL EXPAND THE SCIENTIFIC IMPACT OF THE PROPOSED STUDY BY ALLOWING US TO IDENTIFY PATTERNS OF XYLAZINE ADULTERATION WITHIN AND ACROSS DRUG CLASSES WITHOUT HAVING TO RELY ON SELF-REPORT TO IDENTIFY STUDY PARTICIPANTS EXPOSED TO XYLAZINE, THUS STRENGTHENING OUR SCIENTIFIC CAPACITY TO MEASURE ITS PSYCHOSOCIAL AND PHYSIOLOGICAL IMPACT. AIM 1: TO EMPLOY CBDC TO DETERMINE XYLAZINE'S OVERALL PREVALENCE IN THE ILLICIT DRUG SUPPLY AND ITS RELATIVE PREVALENCE IN SPECIFIC DRUGS CONSUMED BY STUDY PARTICIPANTS; AIM 2: TO EXPLORE KNOWLEDGE AND DISCERNMENT STRATEGIES AMONG CONSUMERS OF ILLICIT DRUGS AS THEY NAVIGATE AN ILLICIT DRUG SUPPLY INCREASINGLY ADULTERATED WITH XYLAZINE; AIM 3: TO EXAMINE THE DRUGS AND DRUG USE BEHAVIORS OF PWUD TO DETERMINE THE PSYCHOSOCIAL CONSEQUENCES, BEHAVIORAL RISKS, AND ADVERSE SEQUALAE ASSOCIATED WITH XYLAZINE EXPOSURE; AIM 4: TO DISSEMINATE REAL-TIME CBDC RESULTS (AIM 1) AND RAPIDLY-ANALYZED STUDY FINDINGS (AIMS 2-3) TO THE STATE/COUNTY HEALTH DEPARTMENTS AND COMMUNITY-BASED ORGANIZATIONS TO INFORM PUBLIC HEALTH RESPONSE . TO ACHIEVE THESE AIMS, WE WILL RECRUIT PWUD FROM TWO STUDY SITES AND THEIR SURROUNDING COUNTIES. THE STUDY WILL BE LED BY PRINCIPAL INVESTIGATOR JON ZIBBELL, A NATIONAL INSTITUTE ON DRUG ABUSE-FUNDED BEHAVIORAL SCIENTIST WITH MANY YEARS OF EXPERIENCE STUDYING INJECTION DRUG USE AND INFECTIOUS DISEASE RISK AMONG PWUD. THE TEAM ALSO INCLUDES ARNIE ALDRIDGE, A NATIONAL INSTITUTES OF HEALTH-FUNDED STATISTICIAN; BRADLEY RAY, A RESEARCH SOCIOLOGIST; AND SARAH DUHART CLARKE, AN APPLIED PSYCHOLOGIST. FINDINGS FROM THE PROPOSED STUDY WILL HELP CLARIFY PREVALENCE OF XYLAZINE AND ILLICIT MARKETS AND IDENTIFY ASSOCIATED BEHAVIORS, OBSERVATIONS, AND ADVERSE SEQUALAE BY DRUG, SET, AND SETTING FACTORS. THE PROPOSED STUDY IS POISED TO DIRECTLY INFORM LOCAL AND NATIONAL EFFORTS FOR COMBATTING HARMS ASSOCIATED WITH XYLAZINE USE BY DISSEMINATING FINDINGS TO COMMUNITY MEMBERS AND DECISIONMAKERS IN REAL-TIME.

Posted 7/5/24, 12:00 AM